Moderna (MRNA) Long-Term Investments (2017 - 2026)

Moderna (MRNA) has 10 years of Long-Term Investments data on file, last reported at $2.3 billion in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $2.3 billion, down 6.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 billion (down 6.91% YoY), and the FY2025 annual result was $2.3 billion, down 6.34% from the prior year.
• Long-Term Investments retreated to $2.3 billion in Q1 2026 per MRNA's latest filing, from $2.3 billion in the prior quarter.
• Over five years, Long-Term Investments peaked at $10.2 billion in Q2 2022 and troughed at $36.0 million in Q1 2023.
• A 5-year average of $4.4 billion and a median of $2.5 billion in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments tumbled 99.61% in 2023, then soared 10005.56% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $8.3 billion in 2022, then tumbled by 43.77% to $4.7 billion in 2023, then plunged by 46.68% to $2.5 billion in 2024, then fell by 6.34% to $2.3 billion in 2025, then decreased by 3.64% to $2.3 billion in 2026.
• Business Quant data shows MRNA's Long-Term Investments at $2.3 billion in Q1 2026, $2.3 billion in Q4 2025, and $2.1 billion in Q3 2025.